Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 252,821 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tiziana Life Sciences Ltd | TLSA | NASDAQ | Depository Receipt |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0515 | -6.12% | 0.7896 | 18:36:46 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.81 | 0.72 | 0.85 | 0.7801 | 0.8411 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 602 | 252,821 | 0.807886 | 204,251 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:36:46 | formt | 2,624 | 0.7896 | USD |
Tiziana Life Sciences Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 80.75M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Tiziana Life Sciences
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
TLSA Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohn's Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products. |
